|  |  |
| --- | --- |
| UHC_Logo_IHP_rgb_Colour | **UHC2030 Steering Committee**  **9th Session – 14 & 15 September 2021**  **Videoconference (Zoom)** |

**Draft Note for the Record**

**For Information**  **For Review & Advice**  **For Approval**

**DRAFT NOTE FOR THE RECORD**

|  |  |
| --- | --- |
| **UHC2030 Steering Committee (virtual) – 8th session, 3 & 4 February 1400-1700 CET** | |
|  | |
| **Objectives of the meeting**   * Agree UHC2030 2021 priorities * Outline aims and contributions towards 2023 UN High Level Meeting on UHC * Agree revised governance/working arrangements   **Summary conclusions**   * 2021 priorities agreed and workplan agreed in principle (final workplan/budget to follow) * Base programme fully-funded for 2021 (contributions from France, Japan, European Commission); sub-group will be mobilized to develop longer-term resource mobilization strategy * SC agreed overall directions for UHC2030 work on accountability * SC noted updates on preparations for UN High Level Meeting on UHC in 2023 and reiterated UHC2030’s importance in mobilizing diverse voices and helping set the agenda for next HLM * SC noted governance updates on Secretariat arrangements, Co-Chairs handover, Private Sector Constituency membership * Next meeting end-June; interim catch-ups/briefings will be scheduled if needed. | |
| **Welcome + Introductions: “Where we’ve come from, where we’re headed”**  ***SC Decisions***   * *Approved Note for Record of June 2020 Steering Committee plus Agenda for this meeting* | |
| ***Co-chairs’ introductions***  **The co-chairs reported positively on UHC2030’s contribution to sustain momentum on UHC commitments in the context of the COVID-19 pandemic over the past 12 months (see progress update document [**UHC2030/SC8/2021/04.Rev1**]), and how this reinforced the importance and unique value of UHC2030 as a multi-stakeholder platform. UHC2030 is well-positioned to keep UHC on the agenda in 2021, promote collective action on UHC commitments, and start gearing up for the UHC high-level meeting in 2023.**  At its previous meeting in June 2020 the Steering Committee (SC) agreed a clear vision and narrative for UHC and COVID-19, building on the Key Asks. Over the past 6 months UHC2030 has:   * **Galvanized political leadership for UHC** in the COVID-19 context, and produced clear messages for political leaders based on the State of UHC Commitment review. * **Promoted a shared vision for UHC and COVID-19**, and action for stronger health systems. * **Continued to promote diverse voices, multi-stakeholder engagement and shared learning** through its unique platforms for civil society, private sector, and health systems partnerships.   To set the scene for the meeting, Co-Chairs outlined the importance of i) setting early expectations for outcomes of, and UHC2030’s role in preparations for, the UN High Level Meeting on UHC in 2023 and ii) continuity of message in 2021, building on the Key Asks and UHC2030 products and statements on COVID-19 and UHC.  ***Welcome incoming Co-Chairs***  This is Ilona Kickbusch and Githinji Gitahi’s last SC meeting as Co-Chairs. They are replaced by **Gabriela Cuevas** and **Justin Koonin**, who shared insights on strategic directions. Gabriela highlighted UHC2030’s role in promoting trust, equality (including gender equality) and justice, including by engaging more with local governments and parliamentarians. Justin said that UHC is first and foremost about people and justice, and that UHC2030 should focus on aligning messages and actions for UHC across diverse constituencies between now and 2023, globally and in countries.  ***Updates***  Progress acknowledged in arrangements for OECD to join the Secretariat alongside WHO and World Bank (see Session 3).  ***Steering committee membership/attendance***  Welcome new members:   * Countries: Tamar Gabunia (Georgia), Jenifer Clark (France), Patrick Banda (Zambia) * United Nations: Fodé Simaga (UNAIDS) * Private Sector: Ed Booty (Reach 52), Ruchika Singhal (Medtronic Labs)   Observer: Bonanza Taihitu (Indonesia), pending SC representative nomination | |
| **Session 1 – “Making it happen in 2021”**  ***Objective: Agree UHC2030 2021 priorities (contributions to ‘health systems that protect everyone')***  **Session 1.1: 2021 priorities – Action on UHC and health systems**  ***SC decisions***   * *2021 priorities agreed:*    + *Ensure UHC (including health systems and common goods for health) is prioritized in COVID-19 response and ‘building back better’;*   + *Promote equitable access to new COVID-19 tools as part of the UHC agenda, emphasizing health systems enablers;*   + *Provide a “now to 2023” strategic vision: what the HLM outcomes should be and how UHC2030 contributes.* | |
| ***Discussion points***   * **The key COVID-19 message for UHC2030 is that countries must invest in health systems**, focusing on common goods for health, foundational investments in human resources, infrastructure and PHC, and health democracy and social participation. This should be linked to the core UHC equity goal reflected in access and financial protection targets. * **COVID-19 vaccination is a clear priority for the world in 2021**, with emphasis on vaccine delivery “into arms”. UHC2030 should promote access to all new COVID-19 tools as part of UHC, including equity both across and within countries, and related health systems enablers. * **UHC2030 role includes promoting interlinkages between UHC, health security, and societies and economies more broadly**. This is relevant for all countries. * **SC members requested that UHC2030 be active in UHC-relevant initiatives such as ACT-A, SDG3-GAP, and the Generation Equality Forum**. UHC2030 can offer unique assets including diversity of membership and ability to mobilise advocacy across stakeholders. * **2023 will be a critical moment to take stock at the SDG midpoint.** UHC2030 can help steer a focus on ‘design issues’ and bottlenecks for making health for all a reality – for example, how to make PHC ‘smart care for everyone’ for countries at all income levels. * **UHC2030 has important roles in accountability, collective action, and bringing health and disease programmes together to champion UHC.** | ***Announcement***   * France announced it will contribute €4 million to UHC2030 over 2 years (from November 2020).   ***Follow up actions (Core Team unless stated otherwise)***   * Explore UHC2030 role in promoting a new Charter for equitable access to tools to combat Covid-19 (as proposed by President Macron at Paris Peace Forum, November 2020) * Re-examine potential UHC2030 work on digital transformation of health systems, ahead of 2023 HLM. * Explore specific UHC2030 roles with ACT-A health systems connector. |
| **Session 1.2: How UHC2030 will deliver on these priorities**  ***SC decisions:***   * *2021 workplan agreed in principle* | |
| ***Discussion points***   * **General support for an ambitious workplan** that builds on achievements and products to date and is well-aligned with priorities agreed in Session 1.1. * **UHC2030 should focus on helping individuals, communities, civil society organisations and parliamentarians be able to say what UHC means for them, and how they can contribute**. By supporting learning around UHC roadmaps and compacts UHC2030 can help countries define ‘rules of the game’ for collective action. UHC2030 should help demonstrate “how to make collective action work” in countries. * **UHC2030 should strengthen collaborations with members/partners on specific products and activities with country impact**. UHC2030’s country presence is entirely through members/partners, and UHC2030 should focus on how to equip country partners for action (relevant tools, learning, etc) – e.g. building on the ‘joint learning agenda’ for health financing advocacy with global health initiatives and civil society. * **UHC2030 is positioned well to build on Social Participation Handbook work** and contribute to a strengthened Voluntary National Reviews process. Accountability work on social participation and budget accountability can be further strengthened by a specific focus, in national and sub-national discussions, on equity and identifying who has been left behind. | ***Follow-up actions***   * Finalise and share workplan and budget incorporating SC feedback * Consider developing i) a UHC guidance product for parliamentarians (making relevant connections with CSEM work on ‘UHC101’ for civil society), ii) a “how to” note on collective action in countries * Explore enhanced collaboration between WHO and civil society in countries, through the UHC Partnership. |
| **Session 1.3: 2021 budget and resource mobilisation**  ***SC decisions***   * *SC noted financial position (2021 base programme fully funded)* | |
| ***Discussion points***   * UHC2030 has turned around its precarious 2020 funding position thanks to a new contribution from France, ongoing support from Japan and the European Commission, and a contribution by WHO. The focus now should be ensuring a more sustainable resource mobilisation strategy for the medium-/long-term. | ***Follow-up actions***   * Mobilize sub-group for longer-term resource mobilisation strategy * Finalise and share ‘case for support’ document. |
| **Session 2 – “The Road to 2023”**  ***Objective: Agree initial strategies and contributions of UHC2030 constituencies to political processes, advocacy and UHC accountability between now and 2023 High Level Meeting on UHC***  **Session 2.1: UHC2030’s role in accountability for UHC**  ***SC decisions***   * *SC welcomed and agreed overall direction of accountability work* | |
| ***Discussion points***   * **The change UHC2030 wants to see is political commitment and collective action on the Key Asks.** This requires that we sustain momentum for action on commitments, promote accountability ahead of the SDGs midpoint, and support communities to hold their governments answerable. * **UHC2030 accountability work must be informed by the State of UHC Commitment review**. This highlighted that inequities (especially gender) are widened by COVID-19, people are anxious about their health, lives and futures, and trust in many governments is lacking and eroding. * **Stepping up social participation is a priority**. This requires both global leadership (e.g. CSO request for social participation leadership group launched by Dr Tedros) and UHC2030 tools/learning to support country processes and platforms that involve civil society and communities. Civil society also called for additional support to country CSOs. * **Linked to this, the Voluntary National Reviews (VNR) process needs strengthening**. Most VNR reports do not speak to UHC. UHC2030 is reaching out to UN and countries and feeding in UHC country profiles and State of Commitment findings. The process must be grounded in and strengthen national dialogues. * **UHC2030 should promote shared messages on health** and shared outcomesbased on quality and equitable health systems and PHC. This means promoting UHC messages for the UN High Level Meeting on HIV/AIDS this year and identifying other opportunities to build strong coalitions across health topics and advocates. * **Global meetings/commitments need more direct translation to country actions**, with countries in the driving seat. There are lots of opportunities to support this through UHC2030’s membership since most members/constituencies are very active in countries. | ***Follow up actions***   * Include in 2021 workplan:   + “What is UHC and how you can help make it happen” product for parliamentarians   + Political statement on role of UHC in economic recovery. * Explore further:   + Ways to promote existing products (from UHC2030 and technical agencies) that support decision-making for UHC   + Ways to step up influencing in countries (starting with SC member countries) plus articulate/track advocacy and accountability results   + Mobilise task team with CSEM to review opportunities for country support with donors/GHIs/UN   + Further dialogue with UHC2030 co-hosts (and wider UHC2030 membership) on how UHC2030’s platform and accountability functions complement implementation by members/partners. |
| **Session 2.2: Gearing up for HLM 2023**  ***SC decisions***   * *No decisions needed; updates on HLM process noted.* | |
| *See slides for UN HLM 2023 milestones anticipated 2021-23*  ***Discussion points***   * **2023 HLM will need to explicitly address health security and global public goods** (e.g. vaccines), informed by the COVID-19 experience and UHC2030 messages on UHC and emergencies. * **There is an expectation that UHC2030 brings diverse voices together ahead of the 2023 HLM.** In 2019 UHC2030 set a shared multi-stakeholder agenda and the Key Asks provided framing for the political declaration and influenced its drafting. * **UHC2030 can help mobilise a shared health agenda**, for example across the HLMs for HIV and UHC and working with civil society. UHC2030 can also bring a valuable focus on the politics of health and a rights-based approach. * **UHC2030 build good relations with New York missions in 2019** and should again have an important role in raising missions’ understanding of UHC issues and level of ambition for HLM outcomes. | ***Follow-up actions***   * Explore further:   + How to bring together different health agendas/constituencies in shared UHC focus at HLM   + Potential survey of people/communities’ health priorities (“how did world do on UHC & your health needs during COVID 19?”) |
| **Session 3 – Governance and working arrangements**  ***Objective: Review proposed revised working arrangements***  ***SC decisions***   * *SC noted updates; no questions/objections raised* | |
| *See slides for updates on*   * *Secretariat host arrangements (OECD joining World Bank and WHO as co-hosts)* * *Private Sector Constituency: change to eligibility criteria (to include relevant not-for-profit entities)* * *Co-Chairs handover* | ***Follow up actions***   * Updated Secretariat arrangements will be shared with SC for approval by email. * Identify a replacement for Gabriela Cuevas on the UHC2030 political advisory panel. |



**UHC2030 Steering Committee**

**9th Session – 14 & 15 September 2021**

**Videoconference (Zoom)**

**List of Participants**

**STEERING COMMITTEE MEMBERS**

**Co-Chairs**

Dr. Githinji GITAHI

Co-Chair, UHC2030 Steering Committee

Chief Executive Officer

AMREF Health Africa

Kenya

Email: Githinji.Gitahi@Amref.org

Professor Ilona KICKBUSCH

Co-Chair, UHC2030 Steering Committee

Director, Global Health Centre

Graduate Institute Geneva

Switzerland

Email: [Ilona.kickbusch@graduateinstitute.ch](mailto:Ilona.kickbusch@graduateinstitute.ch)

**Countries**

Dr Mohsen ASADI-LARI (unable to join)

Assistant Minister of Health and Medical

Education

Ministry of Health and Medical Education

Iran (Islamic Republic of)

Email: [mohsen.asadi@yahoo.com](mailto:mohsen.asadi@yahoo.com)

Dr Patrick BANDA

Assistant Director, Budgeting and Planning

Ministry of Health

Zambia

Email: [patrickbnd@yahoo.co.uk](mailto:patrickbnd@yahoo.co.uk)

Ms Jenifer CLARK

Head of Global Health Policy

Human Development Department

Ministry of Europe and Foreign Affairs

France

Email: [jenifer.clark@diplomatie.gouv.fr](mailto:jenifer.clark@diplomatie.gouv.fr)

Dr Satoshi EZOE

Director

Global Health Policy Division

International Cooperation Bureau

Ministry of Foreign Affairs

Japan

Email: [satoshi.ezoe@mofa.go.jp](mailto:satoshi.ezoe@mofa.go.jp)

Ms Tamar GABUNIA

First Deputy Minister of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs

Georgia

Email: [tgabunia@moh.gov.ge](mailto:tgabunia@moh.gov.ge)

Dr Bernd APPELT

Directorate-General for International Partnerships

European Commission

Belgium

Email: [bernd.appelt@giz.de](mailto:bernd.appelt@giz.de)

Dr Emmanuel ODAME

Director, Policy, Planning and Monitoring and Evaluation

Ministry of Health

Ghana

Email: [joeankra@yahoo.com](mailto:joeankra@yahoo.com)

Dr Aquina Thulare

Technical Specialist, Health Economics/National Health Insurance

Department of Health

South Africa

Email: [Aquina.Thulare@health.gov.za](mailto:ThulaA@health.gov.za)

Mr Bonanza Taihitu

Health and Human Rights Coordinator

Permanent Mission of the Republic of Indonesia to the United Nations

Switzerland

Email: [bonanza.taihitu@mission-indonesia.org](mailto:bonanza.taihitu@mission-indonesia.org)

**Civil Society Organizations (CSOs)**

Mr Javier Luis HOURCADE BELLOCQ

Founder and Editor

Key Correspondents Team for Latin America and Hispanic Carribean

Argentina

Email: [Javier.bellocq@gmail.com](mailto:Javier.bellocq@gmail.com)

Dr Justin KOONIN

President

ACON

Australia

Email: [president@acon.org.au](mailto:president@acon.org.au)

Dr Khuat Thi Hai OANH

Executive Director

Center for Supporting Community Development

Initiatives (SCDI)

Viet Nam

Email: oanhkhuat@scdi.org.vn

**Foundations**

Ms Kate DODSON

Vice President for Global Health

United Nations Foundation

United States

Email: [kdodson@unfoundation.org](mailto:kdodson@unfoundation.org)

**Private sector**

Mr Edward BOOTY

Chief Executive Officer

Allied World Asia (formerly Reach52)

Singapore

Email: [edward@reach52.com](mailto:edward@reach52.com)

Ms Ruchika SINGHAL

Vice President

Medtronic Labs

United States

Email: [ruchika.singhal@medtronic.com](mailto:ruchika.singhal@medtronic.com)

**Multilateral organizations**

Ms Francesca COLOMBO

Head of Health Division

Organisation for Economic Cooperation and

Development

France

Email: [Francesca.Colombo@oecd.org](mailto:Francesca.Colombo@oecd.org)

Mr Bruno RIVALAN

Senior Partnership Specialist

Global Financing Facility

World Bank

United States

Email: [brivalan@worldbank.org](mailto:brivalan@worldbank.org)

Dr Fodé SIMAGA

Director a.i.

Fast Track Implementation Department

Joint United Nations Programme on HIV/AIDS (UNAIDS)

Switzerland

Email: [simagaf@unaids.org](mailto:simagaf@unaids.org)

**World Bank**

Dr Feng ZHAO

Manager for Strategy, Operations and Global Engagement

Health, Nutrition and Population – Global Practice

World Bank Group

United States of America

Email: [fzhao@worldbank.org](mailto:fzhao@worldbank.org)

*Representing Dr Muhammad Ali Pate*

*Global Director, Health, Nutrition and Population*

**World Health Organization**

Dr Agnes SOUCAT

Director

Health Systems Governance and Financing

World Health Organization

Switzerland

Email: [soucata@who.int](mailto:soucata@who.int)

**Other participants**

Dr Lakshmi BALAJI

Senior Adviser and Chief of HSS unit

Health Section, Programme Division

United Nations Children International Emergency Fund (UNICEF)

United States of America

Email: [lnbalaji@unicef.org](mailto:lnbalaji@unicef.org)

Ms Anamaria BEJAR

Director of Advocacy at the International Planned Parenthood Federation

United Kingdom

Email: [awg@ippf.org](mailto:awg@ippf.org)

Ms Amy BOLDOSSER-BOESCH

Senior Director FCI Program

Management Sciences for Health

United States

Email: [aboldosserboesch@msh.org](mailto:aboldosserboesch@msh.org)

Mr Romain CHAVE

Rédacteur, Global health policy

Human development department

Ministry of Europe and Foreign Affairs

France

Email: [romain.chave@diplomatie.gouv.fr](mailto:romain.chave@diplomatie.gouv.fr)

Ms Gabriela CUEVAS BARRON

Incoming UHC2030 Steering Committee Co-Chair

Former President of the Inter-Parliamentary Union (IPU)

Mexico

Email: [gcb1979@yahoo.com](mailto:gcb1979@yahoo.com)

Dr Silviu DOMENTE

WHO Representative

Georgia

Email: [domentes@who.int](mailto:domentes@who.int)

Mr Kurt FRIEDER

President, Fundacion Huesped

Argentina

UHC2030 Civil Society Engagement Mechanism (CSEM)

Email: [kurt.frieder@huesped.org.ar](mailto:kurt.frieder@huesped.org.ar)

Mr Daniel GARCIA

Parliamentary Liaison

Office of Ms Gabriela Cuevas Barron

Mexico

Email: [danielgarcia.ipu@gmail.com](mailto:danielgarcia.ipu@gmail.com)

Ms Katie HUSSELBY

Coordinator, Action for Global Health

United Kingdom

UHC2030 Civil Society Engagement Mechanism (CSEM)

Email: [Katie@actionforglobalhealth.org.uk](mailto:Katie@actionforglobalhealth.org.uk)

Mr Daiki INABA

Deputy Director

Global Health Policy Division

Ministry of Foreign Affairs

Japan

Ëmail: [daiki.inaba@mofa.go.jp](mailto:daiki.inaba@mofa.go.jp)

Mr Cary JAMES

Chief Executive Officer

World Hepatitis Alliance

Switzerland

Email: [cary.james@worldhepatitisalliance.org](mailto:cary.james@worldhepatitisalliance.org)

Ms Evalin K. KARIJO

Project Director

Y-ACT, Youth in Action

Amref Health Africa Headquarters

Kenya

Email: evalin.karijo@amref.org

Ms Eliana MONTEFORTE

Coordinator

UHC2030 Civil Society Engagement Mechanism (CSEM) Secretariat

Management Sciences for Health

United States

Email: [emonteforte@msh.org](mailto:emonteforte@msh.org)

Ms Molly MOSS

Global Health Policy Associate

UN Foundation

United States

Email: [mmoss@unfoundation.org](mailto:mmoss@unfoundation.org)

Ms Maia NIKOLEISHVILI

Chef Specialist

Ministry of Labour, Health and Social Affairs Georgia

Email: [mnikoleishvili@moh.gov.ge](mailto:mnikoleishvili@moh.gov.ge)

Dr Matthias REINICKE

Health Advisory Service

European Commission

Belgium

Email: [mwreinicke@gmail.com](mailto:mwreinicke@gmail.com)

Ms Smitha SADASIVAN

Member, Managing Committee

Multiple Sclerosis Society of India

India

Email: [mschennaichap@gmail.com](mailto:mschennaichap@gmail.com)

Ms Olesya STRUK

Senior Director, Group Sustainability

Royal Philips

Netherlands

Email: [Oleya.Struk@philips.com](mailto:Oleya.Struk@philips.com)

Dr Gang SUN

Senior Advisor, Fast Track Implementation Department

UNAIDS

Switzerland

Email: [sung@unaids.org](mailto:sung@unaids.org)

Mr Nick TOMLINSON

Global Health Advisor

Organisation for Economic Cooperation and

Development

France

Email: [Nick.Tomlinson@oecd.org](mailto:Nick.Tomlinson@oecd.org)

Ms Antonia WELLMANN

Deutsche Gesellschaft für Zusammenarbeit (GIZ) GmbH

Germany

Email: [Antonia.Wellmann@giz.de](mailto:Antonia.Wellmann@giz.de)

Mr Philipe WEALER

Attaché, Coopération et Action humanitaire, santé

Permanent Mission of the Grand Duchy of Luxembourg to the United Nations Office and other international organizations in Geneva

Switzerland

Email: [philippe.wealer@gmail.com](mailto:philippe.wealer@gmail.com)

Mr Douglas WEBB

Team Leader

Health, Gender and Environment

United Nations Development Programme

United States of America

Email: [douglas.webb@undp.org](mailto:douglas.webb@undp.org)

Dr Willibald ZECK

Global Maternal and Newborn Thematic Fund Coordinator

United Nations Population Fund

United States of America

Email: zeck@unfpa.org

**UHC2030 Core Team**

Mr Richard GREGORY

Senior Health Adviser, UHC2030 Core Team

Health Systems Governance and Financing

World Health Organization

Switzerland

Email : [gregoryr@who.int](mailto:gregoryr@who.int)

Ms Kazumi INDEN

Health Specialist, UHC2030 Core Team

Health, Nutrition and Population Global Practice

World Bank

United States of America

Email: [kinden@worldbank.org](mailto:kinden@worldbank.org)

Ms Marjolaine NICOD

Joint Lead, UHC2030 Core Team

Health Systems Governance and Financing

World Health Organization

Switzerland

Email: [nicodm@who.int](mailto:nicodm@who.int)